Stem cell transplantation for multiple myeloma

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Purpose of review Autologous stem cell transplantation (SCT) has been an integral part of the management of multiple myeloma, especially for younger patients. During the past decade, several highly effective therapies have become available for treatment of myeloma, raising questions about the role of SCT for its management. This review focuses on recent findings in the context of previous studies demonstrating a benefit for SCT compared with conventional therapies. Recent findings Recent clinical trials have primarily focused on improving patient outcome by integrating the novel agents into various stages of myeloma therapy, including initial therapy resulting in improvement of disease control at the time of SCT, incorporation into conditioning regimens and finally, using maintenance approaches to prolong the response from SCT. In addition, recent trials also have demonstrated a potential role for tandem SCT in selected patients. However, the role of allogeneic SCT still remains to be better defined. Summary Patients with myeloma have more effective choices for therapy today and better outcome. Recent and ongoing trials will allow better selection of therapy, preferably in an individualized fashion, potentially translating into prolonged survival.

Original languageEnglish (US)
Pages (from-to)162-170
Number of pages9
JournalCurrent Opinion in Oncology
Issue number2
StatePublished - Mar 2009


  • Allogeneic
  • Autologous
  • Multiple myeloma
  • Stem cell transplantation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Stem cell transplantation for multiple myeloma'. Together they form a unique fingerprint.

Cite this